{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:05:48Z","timestamp":1779440748610,"version":"3.53.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Anhui Province Teaching Research Program","award":["2023jyxm0347"],"award-info":[{"award-number":["2023jyxm0347"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Machine Learning (ML) models have achieved outstanding performance in predicting post-surgical survival. However, the \u201cblack-box\u201d nature of ML models restricts their clinical application. This study aims to develop and validate a clinically feasible, machine learning-based online prediction system for predicting the 5-year survival status of patients with prostate cancer (PCa) after surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study conducted a retrospective analysis of clinical data from 300 older adults with PCa aged\u2009\u2265\u200965 years. LASSO regression, random forest (RF), and recursive feature elimination (RFE) were employed to screen for clinical parameters. Subsequently, the cohort was split into a training set and a test set at a 7:3 ratio, and 25 machine learning approaches were utilized for comparative assessment to determine the optimal model. Calibration curves were applied to evaluate the performance of each model, while decision curve analysis (DCA) was adopted to assess their clinical usefulness. In addition, SHAP (Shapley Additive exPlanations) values were used to interpret the model features. Finally, the Shiny framework was employed to develop an online prediction system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The intersection of the three feature selection algorithms identified 13 clinical parameters: Age, ALB, BUN, CRE, HB, PLT, PT, PSA, GS, PNI, PSM, pT and pN. Comparing 25 machine learning algorithms, LightGBM gave the best results. Its performance metrics were: Accuracy 0.9328, Sensitivity 0.9074, Specificity 0.9538, Positive Predictive Value (PPV) 0.9418, Negative Predictive Value (NPV) 0.9118, AUC 0.9778, Recall 0.9074, F1 Score 0.9143. SHAP values revealed the contribution of each feature in the LightGBM model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study successfully developed a 5-year postoperative survival prediction model for prostate cancer patients. The model demonstrated favorable predictive performance in the test set, which may provide a reference for clinical decision-making. Further multi-center external validation is required to clarify its clinical application value in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-026-07551-2","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:54:31Z","timestamp":1777902871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Explainable and visualizable machine learning model development and validation for 5-year postoperative survival prediction in prostate cancer patients aged\u2009\u2265\u200965 years"],"prefix":"10.1186","volume":"26","author":[{"given":"Huaying","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"3","key":"7551_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"7551_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409\u201336. https:\/\/doi.org\/10.3322\/caac.21731.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7551_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"7551_CR4","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2023 (GBD 2023). Seattle, United States: Institute for Health Metrics and Evaluation (IHME). 2025. Available from: https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"issue":"12","key":"7551_CR5","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1002\/ijc.32961","volume":"146","author":"B Wu","year":"2020","unstructured":"Wu B, Lu X, Shen H, et al. Intratumoral heterogeneity and genetic characteristics of prostate cancer. Int J Cancer. 2020;146(12):3369\u201378. https:\/\/doi.org\/10.1002\/ijc.32961.","journal-title":"Int J Cancer"},{"issue":"1","key":"7551_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prnil.2023.07.004","volume":"12","author":"S Panaiyadiyan","year":"2024","unstructured":"Panaiyadiyan S, Kumar R. Prostate cancer nomograms and their application in Asian men: a review. Prostate Int. 2024;12(1):1\u20139. https:\/\/doi.org\/10.1016\/j.prnil.2023.07.004.","journal-title":"Prostate Int"},{"issue":"1","key":"7551_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.prnil.2023.10.003","volume":"12","author":"A L\u00f3pez-Abad","year":"2024","unstructured":"L\u00f3pez-Abad A, Ram\u00edrez Backhaus M, Server G\u00f3mez G, et al. Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study. Prostate Int. 2024;12(1):20\u20136. https:\/\/doi.org\/10.1016\/j.prnil.2023.10.003.","journal-title":"Prostate Int"},{"issue":"24","key":"7551_CR8","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017;317(24):2532\u201342. https:\/\/doi.org\/10.1001\/jama.2017.7248.","journal-title":"JAMA"},{"issue":"4","key":"7551_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.6004\/jnccn.2020.7633","volume":"19","author":"AB Chen","year":"2021","unstructured":"Chen AB, Niu J, Cronin AM, Shih YT, Giordano S, Schrag D. Variation in Use of High-Cost Technologies for Palliative Radiation Therapy by Radiation Oncologists. J Natl Compr Canc Netw. 2021;19(4):421\u201331. https:\/\/doi.org\/10.6004\/jnccn.2020.7633. Published 2021 Feb 12.","journal-title":"J Natl Compr Canc Netw"},{"key":"7551_CR10","unstructured":"Ferlay JEM, Lam F, Colombet M, Mery L, Pineros et al. Global Cancer Observatory: Cancer Tomorrow; International Agency for Research on Cancer: Lyon, France. Available online: https:\/\/gco.iarc.fr\/tomorrow."},{"issue":"9","key":"7551_CR11","first-page":"718","volume":"42","author":"ZT Fu","year":"2020","unstructured":"Fu ZT, Guo XL, Zhang SW, et al. Analysis of incidence and death of prostate cancer in China in 2015. Chin J Oncol. 2020;42(9):718\u201322.","journal-title":"Chin J Oncol"},{"issue":"3","key":"7551_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3760\/cma.j.cn112152-20240119-00035","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, et al. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221\u201331. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20240119-00035.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"7551_CR13","first-page":"29","volume":"44","author":"J He","year":"2022","unstructured":"He J, Chen WQ, Li N, et al. Guidelines for screening, early diagnosis, and early treatment of prostate cancer in China (2022, Beijing). Chin J Oncol. 2022;44(1):29\u201353.","journal-title":"Chin J Oncol"},{"issue":"2","key":"7551_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/PAP.0000000000000425","volume":"31","author":"S Satturwar","year":"2024","unstructured":"Satturwar S, Parwani AV. Artificial Intelligence-Enabled Prostate Cancer Diagnosis and Prognosis: Current State and Future Implications. Adv Anat Pathol. 2024;31(2):136\u201344. https:\/\/doi.org\/10.1097\/PAP.0000000000000425.","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"7551_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13755-023-00264-5","volume":"12","author":"S Ren","year":"2023","unstructured":"Ren S, Li J, Dorado J, et al. From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine. Health Inf Sci Syst. 2023;12(1):6. https:\/\/doi.org\/10.1007\/s13755-023-00264-5. Published 2023 Dec 18.","journal-title":"Health Inf Sci Syst"},{"issue":"1","key":"7551_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41591-021-01620-2","volume":"28","author":"W Bulten","year":"2022","unstructured":"Bulten W, Kartasalo K, Chen PC, et al. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nat Med. 2022;28(1):154\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01620-2.","journal-title":"Nat Med"},{"issue":"4","key":"7551_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/his.14711","volume":"81","author":"JG Kench","year":"2022","unstructured":"Kench JG, Amin MB, Berney DM, et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology. 2022;81(4):447\u201358. https:\/\/doi.org\/10.1111\/his.14711.","journal-title":"Histopathology"},{"issue":"11","key":"7551_CR18","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1111\/cas.16327","volume":"115","author":"S Tang","year":"2024","unstructured":"Tang S, Zhang H, Liang J, et al. Prostate cancer treatment recommendation study based on machine learning and SHAP interpreter. Cancer Sci. 2024;115(11):3755\u201366. https:\/\/doi.org\/10.1111\/cas.16327.","journal-title":"Cancer Sci"},{"key":"7551_CR19","doi-asserted-by":"publisher","first-page":"e2300083","DOI":"10.1200\/CCI.23.00083","volume":"7","author":"S Hu","year":"2023","unstructured":"Hu S, Chang CP, Snyder J, et al. Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO Clin Cancer Inf. 2023;7:e2300083. https:\/\/doi.org\/10.1200\/CCI.23.00083.","journal-title":"JCO Clin Cancer Inf"},{"issue":"2","key":"7551_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/cmb.2020.0188","volume":"28","author":"K Syed","year":"2021","unstructured":"Syed K, Sleeman W, Soni P, et al. Machine-Learning Models for Multicenter Prostate Cancer Treatment Plans. J Comput Biol. 2021;28(2):166\u201384. https:\/\/doi.org\/10.1089\/cmb.2020.0188.","journal-title":"J Comput Biol"},{"issue":"6","key":"7551_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.eururo.2018.09.050","volume":"75","author":"GB Auffenberg","year":"2019","unstructured":"Auffenberg GB, Ghani KR, Ramani S, et al. askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men. Eur Urol. 2019;75(6):901\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.050.","journal-title":"Eur Urol"},{"issue":"1","key":"7551_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/bju.14477","volume":"123","author":"NC Wong","year":"2019","unstructured":"Wong NC, Lam C, Patterson L, Shayegan B. Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy. BJU Int. 2019;123(1):51\u20137. https:\/\/doi.org\/10.1111\/bju.14477.","journal-title":"BJU Int"},{"key":"7551_CR23","doi-asserted-by":"publisher","unstructured":"Zhou C, Zhang YF, Guo S et al. Multimodal data integration for predicting progression risk in castration-resistant prostate cancer using deep learning: a multicenter retrospective study. Front Oncol. 2024;14:1287995. https:\/\/doi.org\/10.3389\/fonc.2024.1287995. Published 2024 Mar 14.","DOI":"10.3389\/fonc.2024.1287995"},{"issue":"13","key":"7551_CR24","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.3390\/cancers15133416","volume":"15","author":"HW Lee","year":"2023","unstructured":"Lee HW, Kim E, Na I, Kim CK, Seo SI, Park H. Novel Multiparametric Magnetic Resonance Imaging-Based Deep Learning and Clinical Parameter Integration for the Prediction of Long-Term Biochemical Recurrence-Free Survival in Prostate Cancer after Radical Prostatectomy. Cancers (Basel). 2023;15(13):3416. https:\/\/doi.org\/10.3390\/cancers15133416. Published 2023 Jun 29.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"7551_CR25","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41416-023-02441-5","volume":"129","author":"Y Hou","year":"2023","unstructured":"Hou Y, Jiang KW, Wang LL, et al. Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence. Br J Cancer. 2023;129(10):1625\u201333. https:\/\/doi.org\/10.1038\/s41416-023-02441-5.","journal-title":"Br J Cancer"},{"issue":"6","key":"7551_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/21681805.2021.1977845","volume":"55","author":"E Polymeri","year":"2021","unstructured":"Polymeri E, Kj\u00f6lhede H, Enqvist O, et al. Artificial intelligence-based measurements of PET\/CT imaging biomarkers are associated with disease-specific survival of high-risk prostate cancer patients. Scand J Urol. 2021;55(6):427\u201333. https:\/\/doi.org\/10.1080\/21681805.2021.1977845.","journal-title":"Scand J Urol"},{"issue":"10","key":"7551_CR27","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s00345-020-03080-8","volume":"38","author":"KC Koo","year":"2020","unstructured":"Koo KC, Lee KS, Kim S, et al. Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system. World J Urol. 2020;38(10):2469\u201376. https:\/\/doi.org\/10.1007\/s00345-020-03080-8.","journal-title":"World J Urol"},{"issue":"1","key":"7551_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12967-019-1920-5","volume":"17","author":"C Hoey","year":"2019","unstructured":"Hoey C, Ahmed M, Fotouhi Ghiam A, et al. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med. 2019;17(1):173. https:\/\/doi.org\/10.1186\/s12967-019-1920-5. Published 2019 May 23.","journal-title":"J Transl Med"},{"issue":"1","key":"7551_CR29","first-page":"4","volume":"65","author":"J Planas","year":"2012","unstructured":"Planas J, Morote J. Criterios de recidiva bioqu\u00edmica despu\u00e9s de prostatectom\u00eda radical. Historia natural de la enfermedad [Biochemical recurrence criteria after radical prostatectomy. Natural history of the disease]. Arch Esp Urol. 2012;65(1):4\u201311.","journal-title":"Arch Esp Urol"},{"key":"7551_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4137\/CMO.S7073","volume":"5","author":"T Inamoto","year":"2011","unstructured":"Inamoto T, Komura K, Watsuji T, Azuma H. Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer. Clin Med Insights Oncol. 2011;5:101\u20136. https:\/\/doi.org\/10.4137\/CMO.S7073.","journal-title":"Clin Med Insights Oncol"},{"issue":"9","key":"7551_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.purol.2008.06.001","volume":"18","author":"H Lamallem","year":"2008","unstructured":"Lamallem H, et al. El\u00e9vation du PSA apr\u00e8s irradiation prostatique: rebond ou r\u00e9cidive biologique? [Elevation of PSA after prostate radiotherapy: rebound or biochemical recurrence?]. Prog Urol. 2008;18(9):557\u201361. https:\/\/doi.org\/10.1016\/j.purol.2008.06.001.","journal-title":"Prog Urol"},{"issue":"9","key":"7551_CR32","first-page":"1283","volume":"124","author":"SJ Xia","year":"2011","unstructured":"Xia SJ, Jing YF. Biochemical recurrence of prostate cancer: the controversial recognition and management. Chin Med J (Engl). 2011;124(9):1283\u20135.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"7551_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2010.10.003","volume":"59","author":"F Abdollah","year":"2011","unstructured":"Abdollah F, Sun M, Thuret R, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988\u20132006. Eur Urol. 2011;59(1):88\u201395. https:\/\/doi.org\/10.1016\/j.eururo.2010.10.003.","journal-title":"Eur Urol"},{"issue":"1","key":"7551_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jncc.2021.11.005","volume":"2","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Ye Y, Chen L, et al. Prevalence and outcomes of focal ablation versus prostatectomy for elderly patients with prostate cancer: a population-based study. J Natl Cancer Cent. 2021;2(1):25\u201332. https:\/\/doi.org\/10.1016\/j.jncc.2021.11.005. Published 2021 Nov 26.","journal-title":"J Natl Cancer Cent"},{"issue":"2","key":"7551_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdx742","volume":"29","author":"A Pettersson","year":"2018","unstructured":"Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdx742.","journal-title":"Ann Oncol"},{"key":"7551_CR36","first-page":"52","volume":"30","author":"QM GuolinKe","year":"2017","unstructured":"GuolinKe QM, Finley T, Wang T, Chen W, Ma W, Ye Q, Liu TY, Lightgbm. A highly efficient gradient boosting decision tree. Adv Neural Inf Process Syst. 2017;30:52.","journal-title":"Adv Neural Inf Process Syst"},{"issue":"8","key":"7551_CR37","doi-asserted-by":"publisher","first-page":"e13872","DOI":"10.1111\/acel.13872","volume":"22","author":"D Bernard","year":"2023","unstructured":"Bernard D, Doumard E, Ader I, et al. Explainable machine learning framework to predict personalized physiological aging. Aging Cell. 2023;22(8):e13872. https:\/\/doi.org\/10.1111\/acel.13872.","journal-title":"Aging Cell"},{"issue":"5","key":"7551_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","volume":"1","author":"C Rudin","year":"2019","unstructured":"Rudin C. Stop Explaining Black Box Machine Learning Models for High Stakes Decisions and Use Interpretable Models Instead. Nat Mach Intell. 2019;1(5):206\u201315. https:\/\/doi.org\/10.1038\/s42256-019-0048-x.","journal-title":"Nat Mach Intell"},{"issue":"14","key":"7551_CR39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/jama.2019.10306","volume":"322","author":"NH Shah","year":"2019","unstructured":"Shah NH, Milstein A, Bagley SC. Making machine learning models clinically useful. JAMA. 2019;322(14):1351\u20132.","journal-title":"JAMA"},{"key":"7551_CR40","doi-asserted-by":"publisher","unstructured":"Liu M, Luo J, Li L et al. Design and development of a disease-specific clinical database system to increase the availability of hospital data in China. Health Inf Sci Syst. 2023;11(1):11. https:\/\/doi.org\/10.1007\/s13755-023-00211-4. Published 2023 Jan 30.","DOI":"10.1007\/s13755-023-00211-4"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-026-07551-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-07551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-07551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:21:42Z","timestamp":1779438102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-026-07551-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7551"],"URL":"https:\/\/doi.org\/10.1186\/s12877-026-07551-2","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and its subsequent revisions. The study was approved by the Bioethics Committee of The First Affiliated Hospital of University of Science and Technology of China (No.2024-RE-272). Informed consent or substitute for it was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"725"}}